Keywords
kardiorenal sindrom
NT-proBNP
albuminuriya,
GFR
How to Cite
Abstract
Arterial gipertoniya (AG) bilan kasallangan bemorlarda kardiorenal sindrom (KRS) rivojlanishining patogenetik mexanizmlarini klinik, laborator va instrumental ko‘rsatkichlar asosida baholash hamda erta diagnostik biomarkerlarni aniqlash. Metodlar: 2024–2025-yillarda prospektiv kuzatuv tarzida o‘tkazilgan tadqiqotga AG tashxisi qo‘yilgan 142 nafar bemor va 30 nafar sog‘lom nazorat guruhi jalb qilindi.
References
1. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal.
2018;39(33):3021-3104. doi:10.1093/eurheartj/ehy339
2. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. Journal of the American College of Cardiology. 2008;52(19):1527- 1539. doi:10.1016/j.jacc.2008.07.051
3. Rangaswami J, Bhalla V, Blair JEA, et al. Cardiorenal syndrome: Classification, pathophysiology, diagnosis, and treatment strategies. Circulation. 2019;139(16):e840-e878. doi:10.1161/CIR.0000000000000664
4. Ma K, Gao W, Xu H, Liang W, Ma G. Role and mechanism of the reninangiotensin-aldosterone system in the onset and development of cardiorenal syndrome. International Journal of Hypertension. 2022;2022:3239057. doi:10.1155/2022/3239057
5. Zannad F, Rossignol P, Iraqi W. Extracellular matrix fibrotic markers in heart failure and cardiorenal syndrome. Heart Failure Reviews. 2018;23(3):319-329. doi:10.1007/s10741-018-9682-1
This work is licensed under a Creative Commons Attribution 4.0 International License.
